Cargando…

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data

Janus kinase (JAK) Inhibitors are the latest drug class of disease-modifying medication to emerge for the treatment of rheumatoid arthritis (RA). They are a small molecule-targeted treatment and are the first oral option to compare favourably to existing biologic disease-modifying anti-rheumatic dru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrington, Robert, Al Nokhatha, Shamma Ahmad, Conway, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500842/ https://www.ncbi.nlm.nih.gov/pubmed/32982367 http://dx.doi.org/10.2147/JIR.S219586

Ejemplares similares

Biologic Therapies for Giant Cell Arteritis
por: Harrington, Robert, et al.
Publicado: (2021)

Association of extended myositis panel results, clinical features, and diagnoses: a single-center retrospective observational study
por: Al Nokhatha, Shamma Ahmad, et al.
Publicado: (2021)

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
por: Harigai, Masayoshi
Publicado: (2019)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
por: Taylor, Peter C
Publicado: (2019)

Clinical use of Jak 1 inhibitors for rheumatoid arthritis
por: Nash, Peter
Publicado: (2021)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2013)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
por: Kotyla, Przemysław J., et al.
Publicado: (2020)

JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
por: Moura, Rita A., et al.
Publicado: (2021)

Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis
por: Wang, Faping, et al.
Publicado: (2022)

Targeted Therapy in Rheumatoid-Arthritis-Related Interstitial Lung Disease
por: Harrington, Robert, et al.
Publicado: (2023)

Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Emery, Paul, et al.
Publicado: (2018)

JAK/STAT pathway in pathology of rheumatoid arthritis (Review)
por: Ciobanu, Dana Alexandra, et al.
Publicado: (2020)

Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis
por: Pei, Heying, et al.
Publicado: (2018)

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
por: Angelini, Jacopo, et al.
Publicado: (2020)

More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
por: Langley, Paul C
Publicado: (2020)

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
por: Fragoulis, George E, et al.
Publicado: (2019)

Pulmonary nodules associated with JAK inhibitor therapy in rheumatoid arthritis: A case report
por: Pannell, N, et al.
Publicado: (2021)

Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
por: Zhang, Ning, et al.
Publicado: (2021)

Myocarditis as a lupus challenge: two case reports
por: Al-Nokhatha, Shamma Ahmad, et al.
Publicado: (2019)

Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?
por: Mehta, Puja, et al.
Publicado: (2020)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

Design of novel JAK3 Inhibitors towards Rheumatoid Arthritis using molecular docking analysis
por: Jain, Divya, et al.
Publicado: (2019)

Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Pope, Janet, et al.
Publicado: (2020)

A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease
por: Tardella, Marika, et al.
Publicado: (2022)

Early response to JAK inhibitors on central sensitization and pain catastrophizing in patients with active rheumatoid arthritis
por: Salaffi, Fausto, et al.
Publicado: (2022)

One of the active ingredients in Paeoniae Radix Alba functions as JAK1 inhibitor in rheumatoid arthritis
por: Xiao, Lu, et al.
Publicado: (2022)

Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2022)

Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
por: Convertino, Irma, et al.
Publicado: (2023)

Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study
por: Yoshida, Shuhei, et al.
Publicado: (2023)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2023)

Negative Regulators of JAK/STAT Signaling in Rheumatoid Arthritis and Osteoarthritis
por: Malemud, Charles J.
Publicado: (2017)

Comparative efficacy and safety of JAK inhibitors and leflunomide in rheumatoid arthritis: A protocol for systematic review and meta-analysis
por: Zhang, Xiaogang, et al.
Publicado: (2022)

A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine–related JAK-STAT signal
por: Chen, Chengjuan, et al.
Publicado: (2022)

Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
por: Kaine, Jeffrey, et al.
Publicado: (2020)

A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease
por: Cronin, Owen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jho32tcc1o8rlb9g73t8gkta8p